Magenta Therapeutics (MGTA) PT Lowered to $8 at Mizuho Securities, but Analyst Maintains Buy Rating, Continues to See Upside from Current Valuation
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan lowered the price target on Magenta Therapeutics (NASDAQ: MGTA) to $8.00 (from $17.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
